PTGS2 and head and neck squamous cell carcinoma: To determine whether ADO and PGE2 play a role in the suppressive activity of Treg in vivo, we measured the frequency of circulating CD39+ and COX-2+ Treg by flow cytometry in cohorts of patients with HNSCC at various disease stages (8, 53, Schuler et al., in revision).